Advanced and Metastatic Esophageal Squamous Cell Carcinoma (ESCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Advanced and Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Market Outlook
Thelansis’s “Advanced and Metastatic
Esophageal Squamous Cell Carcinoma (ESCC) Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers
disease overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Advanced
and Metastatic Esophageal Squamous Cell Carcinoma (ESCC) treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Advanced
and Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Overview
Advanced
and metastatic Squamous cell esophageal carcinoma is typically diagnosed at
later stages of the disease, often necessitating extensive surgical resection,
occasionally in combination with perioperative chemotherapy or neoadjuvant
radiochemotherapy. The manifestation of advanced and metastatic Squamous cell
esophageal carcinoma is marked by tumor growth, leading to symptoms that
include the gradual loss of the ability to swallow solid foods, followed by
difficulty ingesting ground food and, ultimately, liquids. In advanced stages,
the disease is characterized by polypoid intraluminal masses and a reduction in
esophageal distensibility, which may or may not be accompanied by luminal
narrowing. The most common complaint in most patients (90%) is progressive
dysphagia, typically observed when more than 50% of the lumen is obstructed or
when the luminal diameter falls below 13 mm. Squamous cell carcinoma accounts
for approximately 90% of all esophageal cancers worldwide and develops from
squamous epithelium, progressing from hyperplasia to dysplasia and eventually
to cancer. At the molecular level, its pathogenesis is linked to the
deregulation of specific genes, notably TP53, NOTCH, and MTOR. Early-stage
esophageal cancers often remain asymptomatic or may present with mild,
nonspecific symptoms like heartburn, atypical chest pain, or dyspepsia.
Alternatively, patients may experience symptoms such as occult blood in their
stool or develop iron deficiency anemia. Some individuals may report mild or
sporadic dysphagia, odynophagia, or a sensation of having a foreign body in
their throat. Typically, these symptoms prompt diagnostic evaluation, which
includes an esophagogastroduodenoscopy (EGD) or upper endoscopy, along with a
diagnostic mucosal biopsy. Early-stage cancers are discovered during routine
upper endoscopic surveillance for Barrett’s esophagus in certain cases. The
symptoms of esophageal cancer tend to progress rapidly.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment